Australia: TGA future business processes on complementary medicines open for discussion

Last Updated: 15 October 2017
Article by Dean Gerakiteys

A standardised process for pre-market assessments of complementary medicines with legislated timeframes and fee structures could be on the way.

As part of the continuing reform of the Australian therapeutic goods regulatory framework, the Therapeutic Goods Administration (TGA) has released a further consultation paper, seeking the views of consumers, health professionals and sponsors on the development and implementation of a range of proposed business processes aimed at improving the regulation of complementary medicines in Australia. Responses are requested by 7 November 2017.

Broadly, comments are invited on the following issues:

  • business processes for pre-market assessment including legislated assessment timeframes and proposed fee structures for applications requiring evaluation;
  • the introduction of risk-based application categories for the pre-market evaluation of complementary medicines;
  • criteria to apply to the acceptance of reports from comparable overseas regulators and sources of evidence for de novo assessment; and
  • strategies to enhance the post-market monitoring and compliance scheme for listed medicines.

Business processes for pre-market assessments including legislated assessment timeframes and proposed fee structures for applications requiring evaluation

The TGA is proposing to introduce a standardised process for pre-market assessments with legislated timeframes and fee structures. The TGA has illustrated the proposed process:

Complementary medicines listed in the "standard" manner, that is, that use only permitted indications, will continue to be listed on the basis of self-assessment/certification.

Each step of the process is detailed further as part of the consultation. Notably:

  • an application fee and evaluation fee will apply. The application fee is payable on submission, and purportedly reflects the administrative costs associated with an application, whereas the evaluation fee will cover the cost of assessing the supporting information in an application. The latter is only payable at "Screening", that is once an application is deemed to meet the minimum requirements to proceed to "Evaluation";
  • "Evaluation" may involve requests for information seeking further clarification. These requests will not however afford an applicant an opportunity to supply information that should have been originally included
  • as part of the "Decision", the delegate will consider the evaluation report as well as any advice provided by an advisory committee and any subsequent comment provided by the applicant.

In support of this process a new fee structure is proposed, reflective of the level of risk of a new or varied complementary medicine and the level of scrutiny required to be undertaken by the TGA for the purposes of the pre-market assessment. At this stage, the TGA has provided initial estimates of the proposed Application and Evaluation fees. The proposed Application fees range from $430 for a listed assessed medicine in the lowest applicable category to $2,770 for a new registered complementary medicine in the highest category, while the proposed Evaluation fees for the same goods range from $1,640 to $35,500.

The proposed timeframes for each of the various assessment pathways range from:

  • 70 to 180 working days for complementary medicine ingredients;
  • 45 to 150 working days for assessed listed medicines; and
  • 45 to 210 working days for registered complementary medicines.

The TGA is seeking feedback on these proposed business processes for pre-market assessments including both the proposed fee structures and legislated timeframes.

Risk-based application categories

The TGA also proposes the introduction of risk-based application categories in the pre-market evaluation of complementary medicines. It is proposed that these application categories will sit within each of the pre-market assessment processes to apply to complementary medicines, namely:

  • new ingredients to be used in listed medicines;
  • assessed listed medicines; and
  • registered medicines.

It is envisaged that applications submitted in the lower risk categories will require less supporting information.

The TGA is seeking feedback on the proposed categories underlying each pre-market assessment as part of this consultation.

Criteria for acceptance of reports from comparable overseas regulators and sources of evidence for de novo assessments

The TGA has detailed the criteria it proposes using to determine whether reports from comparable overseas regulators are able to be relied upon by sponsors for the purposes of applications for assessment. The criteria have been designed to be applied through a two-stage process:

  • firstly, the preliminary criteria that will be used to determine if there is sufficient similarity between the TGA and the overseas regulator; and
  • secondly, the parameters that the TGA will consider to determine the suitability of evaluation reports from overseas regulators at the time of submission.

The TGA has also detailed the criteria it proposes be applied to alternative sources of evidence for de novo assessments.

The TGA is seeking feedback on both the criteria for acceptance of reports from comparable overseas regulators and sources of evidence for de novo assessments, which are set out in further detail in the consultation paper.

Enhanced post-market compliance monitoring scheme for listed medicines

The TGA has expressed concerns about the level of non-compliance by sponsors of listed medicines and has proposed three strategies to address this issue:

  • Targeting of non-compliant sponsors. The TGA has noted that currently sponsors may withdraw their product from the ARTG following a request for information for a compliance review, only to later relist their medicine so as to avoid a possible negative finding. The TGA proposes disincentivising this behaviour by targeting such sponsors for post-market compliance review for multiple listed medicines, at least until such time as, in the opinion of the TGA, the sponsor's behaviours and actions improve. The TGA also proposes penalising sponsors who repeatedly demonstrate a clear intention to circumvent their obligations. The example given is the use of infringement notices for repeat offenders;
  • Improving transparency about compliance review outcomes. The TGA proposes providing more detailed information about products that are the subject of a compliance review, including the compliance issues identified during any such review, the actions taken by the sponsor in response; and/or if the product is cancelled, details as to the reasons why the product was cancelled. The TGA acknowledges that this will involve a balancing act between consumer protection and the protection of commercial information and procedural fairness; and
  • Education and resources for product sponsors. The TGA proposes educating sponsors with better tools and resources to improve their understanding of their regulatory obligations.

The TGA is seeking feedback on the measures proposed above, including the educative tools that may result in greater compliance.


Clayton Utz communications are intended to provide commentary and general information. They should not be relied upon as legal advice. Formal legal advice should be sought in particular transactions or on matters of interest arising from this bulletin. Persons listed may not be admitted in all states and territories.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions